Literature DB >> 28084680

Rapid and fulminant leptomeningeal spread following radiotherapy in diffuse intrinsic pontine glioma.

Christopher L Tinkle1, Brent A Orr2, John T Lucas1, Paul Klimo3, Zoltan Patay4, Suzanne J Baker5, Alberto Broniscer6, Ibrahim Qaddoumi6.   

Abstract

A 4-year-old male presented with rapid-onset cranial nerve palsy and ataxia. Brain magnetic resonance imaging (MRI) revealed a pontine mass lesion with discordant conventional and advanced imaging. A stereotactic core biopsy revealed glioblastoma with immunostaining suggestive of histone H3K27M and TP53 mutation, consistent with diffuse intrinsic pontine glioma. MRI 3 months after radiotherapy revealed extensive new leptomeningeal metastatic disease involving both the supra- and infratentorial brain, as well as the imaged portion of the spine. Tissue procured at the time of needle biopsy has undergone striking in vivo expansion as an orthotopic xenograft.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  H3K27M; hypofractionated radiotherapy; leptomeningeal metastasis; pontine glioma; stereotactic biopsy; xenograft

Mesh:

Year:  2017        PMID: 28084680      PMCID: PMC5796806          DOI: 10.1002/pbc.26416

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  20 in total

1.  Randomized trial on radiotherapy for paediatric diffuse intrinsic pontine glioma (DIPG).

Authors:  Daniel E Roos; Jennifer G Smith
Journal:  Radiother Oncol       Date:  2014-11-28       Impact factor: 6.280

2.  Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?

Authors:  Arya Amini; Basel Altoos; Maria T Bourlon; Edward Bedrick; Shilpa Bhatia; Elizabeth R Kessler; Thomas W Flaig; Christine M Fisher; Brian D Kavanagh; Elaine T Lam; Sana D Karam
Journal:  Pract Radiat Oncol       Date:  2015-06-30

3.  Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.

Authors:  Michelle Monje; Siddhartha S Mitra; Morgan E Freret; Tal B Raveh; James Kim; Marilyn Masek; Joanne L Attema; Gordon Li; Terri Haddix; Michael S B Edwards; Paul G Fisher; Irving L Weissman; David H Rowitch; Hannes Vogel; Albert J Wong; Philip A Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-01       Impact factor: 11.205

4.  Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis.

Authors:  Geert O Janssens; Marc H Jansen; Selmer J Lauwers; Peter J Nowak; Foppe R Oldenburger; Eric Bouffet; Frank Saran; Karin Kamphuis-van Ulzen; Erik J van Lindert; Jolanda H Schieving; Tom Boterberg; Gertjan J Kaspers; Paul N Span; Johannes H Kaanders; Corrie E Gidding; Darren Hargrave
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-09       Impact factor: 7.038

5.  Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.

Authors:  Nathalène Truffaux; Cathy Philippe; Janna Paulsson; Felipe Andreiuolo; Léa Guerrini-Rousseau; Gaétan Cornilleau; Ludivine Le Dret; Catherine Richon; Ludovic Lacroix; Stéphanie Puget; Birgit Geoerger; Gilles Vassal; Arne Östman; Jacques Grill
Journal:  Neuro Oncol       Date:  2014-12-21       Impact factor: 12.300

6.  Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience.

Authors:  Laura Negretti; Karim Bouchireb; Christine Levy-Piedbois; Jean Louis Habrand; Frederic Dhermain; Chantal Kalifa; Jacques Grill; Christelle Dufour
Journal:  J Neurooncol       Date:  2011-02-17       Impact factor: 4.130

7.  Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment.

Authors:  Rintaro Hashizume; Ivan Smirnov; Sharon Liu; Joanna J Phillips; Jeanette Hyer; Tracy R McKnight; Michael Wendland; Michael Prados; Anu Banerjee; Theodore Nicolaides; Sabine Mueller; Charles D James; Nalin Gupta
Journal:  J Neurooncol       Date:  2012-09-17       Impact factor: 4.130

8.  Hypofractionated Radiotherapy for Children With Diffuse Intrinsic Pontine Gliomas.

Authors:  Todd C Hankinson; Mohana Rao Patibandla; Adam Green; Molly Hemenway; Nicholas Foreman; Michael Handler; Arthur K Liu
Journal:  Pediatr Blood Cancer       Date:  2015-11-06       Impact factor: 3.167

9.  Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group.

Authors:  A L Albright; R J Packer; R Zimmerman; L B Rorke; J Boyett; G D Hammond
Journal:  Neurosurgery       Date:  1993-12       Impact factor: 4.654

10.  Targeting Wee1 for the treatment of pediatric high-grade gliomas.

Authors:  Sabine Mueller; Rintaro Hashizume; Xiaodong Yang; Ilan Kolkowitz; Aleksandra K Olow; Joanna Phillips; Ivan Smirnov; Maxwell W Tom; Michael D Prados; C David James; Mitchel S Berger; Nalin Gupta; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

View more
  3 in total

1.  Leptomeningeal disease and tumor dissemination in a murine diffuse intrinsic pontine glioma model: implications for the study of the tumor-cerebrospinal fluid-ependymal microenvironment.

Authors:  Shelei Pan; Dezhuang Ye; Yimei Yue; Lihua Yang; Christopher P Pacia; Dakota DeFreitas; Prabagaran Esakky; Sonika Dahiya; David D Limbrick; Joshua B Rubin; Hong Chen; Jennifer M Strahle
Journal:  Neurooncol Adv       Date:  2022-04-26

2.  Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.

Authors:  Linmao Zheng; Jing Gong; Tianping Yu; Yan Zou; Mengni Zhang; Ling Nie; Xueqin Chen; Qiang Yue; Yanhui Liu; Qing Mao; Qiao Zhou; Ni Chen
Journal:  Am J Surg Pathol       Date:  2022-04-13       Impact factor: 6.298

3.  H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.

Authors:  Bette K Kleinschmidt-DeMasters; Jean M Mulcahy Levy
Journal:  Clin Neuropathol       Date:  2018 Mar/Apr       Impact factor: 1.368

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.